- Eradication of HCV improves glucose metabolism regardless of diabetes mellitus (DM) status.
Why this matters
- Viral-induced insulin resistance is linked to liver fibrosis progression.
- Study population was 82 HCV-RNA-positive patients without known diabetes, receiving direct antivirals.
- All underwent a standard oral glucose tolerance test before and immediately after antiviral treatment.
- Funding: None.
- At treatment end, HCV-RNA quantification was below detection threshold in all cases.
- Significant reductions from pre- to posttreatment occurred in:
- Fasting plasma glucose: 94 to 92 mg/dL (P=.028);
- 2-hour postglucose load: 132 to 114 mg/dL (P<.001>
- HbA1c: 5.5% to 5.4% (P=.008); and
- Homeostasis model assessment of insulin resistance (HOMA-IR): 3.42 to 2.80 (P<.001>
- 37 (45%) had normal glucose tolerance (NGT),
- 31 (38%) prediabetes, and
- 14 (17%) diabetes.
- Small sample size.
- Many had advanced liver disease (52% cirrhosis; 38% advanced liver fibrosis).
- Heterogeneity of viral genotypes.